NASDAQ : NNNN
Anbio Biotechnology — Key statistics
Healthcare · Medical Instruments & Supplies · Germany
Last price 3.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 163.28M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 156.25M |
| Enterprise Value | 144.35M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 43.89M |
| Shares Outstanding | 43.89M |
| Shares Change (YoY) | +3.27% |
| Shares Change (QoQ) | +1.03% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.30% |
| Float | 39.69M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 24.28 |
| Forward PE | n/a |
| PS Ratio | 17.06 |
| Forward PS | n/a |
| PB Ratio | 4.89 |
| P/TBV Ratio | 4.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 21.17 |
| EV / Sales | 15.68 |
| EV / EBITDA | n/a |
| EV / EBIT | 23.51 |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 344.31 |
| Quick Ratio | 177.13 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 27.05% |
| Return on Assets (ROA) | 14.66% |
| Return on Invested Capital (ROIC) | 15.23% |
| Return on Capital Employed (ROCE) | 19.13% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $320,253 |
| Profits Per Employee | $237,165 |
| Employee Count | 27 |
| Asset Turnover | 0.35 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | -78.93% |
| 50-Day Moving Average | 5.40 |
| 200-Day Moving Average | 17.18 |
| Relative Strength Index (RSI) | 34.16 |
| Average Volume (20 Days) | 54,217 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 31,124 |
| Short Previous Month | 54,022 |
| Short % of Shares Out | 0.07% |
| Short % of Float | 0.08% |
| Short Ratio (days to cover) | 0.23 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 8.65M |
| Gross Profit | 7.54M |
| Operating Income | 5.77M |
| Pretax Income | 6.40M |
| Net Income | 6.40M |
| EBITDA | n/a |
| EBIT | 5.77M |
| Earnings Per Share (EPS) | $0.15 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 11.90M |
| Total Debt | n/a |
| Net Cash | 11.90M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 30.16M |
| Book Value Per Share | 0.69 |
| Working Capital | 30.16M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -6.74M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -6.74M |
| FCF Per Share | -$0.15 |
Margins
| Measure | Value |
|---|
| Gross Margin | 87.24% |
| Operating Margin | 66.70% |
| Pretax Margin | 74.06% |
| Profit Margin | 74.06% |
| EBITDA Margin | n/a |
| EBIT Margin | 66.70% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.27% |
| Shareholder Yield | -3.27% |
| Earnings Yield | 4.12% |
| FCF Yield | -4.57% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |